> top > docs > PubMed:20828385 > annotations

PubMed:20828385 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCoin-sentences

Id Subject Object Predicate Lexical cue
T1 0-90 Sentence denotes Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma.
T2 91-181 Sentence denotes Mantle cell lymphoma (MCL) is a rare and aggressive type of B-cell non-Hodgkin's lymphoma.
T3 182-281 Sentence denotes Patients become progressively refractory to conventional chemotherapy, and their prognosis is poor.
T4 282-574 Sentence denotes However, a 38% remission rate has been recently reported in refractory MCL treated with temsirolimus, a mTOR inhibitor.Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after temsirolimus treatment, and a progression-free survival of 10 months.
T5 575-673 Sentence denotes In this case, lymph node biopsies were performed before and six months after temsirolimus therapy.
T6 674-861 Sentence denotes Comparison of the two biopsies showed that temsirolimus inhibited tumor cell proliferation through cell cycle arrest, but did not induce any change in the number of apoptotic tumor cells.
T7 862-1005 Sentence denotes Apart from this cytostatic effect, temsirolimus had an antiangiogenic effect with decrease of tumor microvessel density and of VEGF expression.
T8 1006-1153 Sentence denotes Moreover, numerous patchy, well-limited fibrotic areas, compatible with post-necrotic tissue repair, were found after 6-month temsirolimus therapy.
T9 1154-1411 Sentence denotes Thus, temsirolimus reduced tumor burden through associated cytostatic and anti-angiogenic effects.This dual effect of temsirolimus on tumor tissue could contribute to its recently reported efficiency in refractory MCL resistant to conventional chemotherapy.

LitCoin-entities

Id Subject Object Predicate Lexical cue db_id
8028 42-54 ChemicalEntity denotes temsirolimus MESH:C401859
8029 69-89 DiseaseOrPhenotypicFeature denotes mantle cell lymphoma MESH:D020522
8030 91-111 DiseaseOrPhenotypicFeature denotes Mantle cell lymphoma MESH:D020522
8031 113-116 DiseaseOrPhenotypicFeature denotes MCL MESH:D020522
8032 151-180 DiseaseOrPhenotypicFeature denotes B-cell non-Hodgkin's lymphoma MESH:D008228
8033 182-190 OrganismTaxon denotes Patients NCBITaxon:9606
8034 353-356 DiseaseOrPhenotypicFeature denotes MCL MESH:D020522
8035 370-382 ChemicalEntity denotes temsirolimus MESH:C401859
8036 386-390 GeneOrGeneProduct denotes mTOR NCBIGene:2475
8037 459-462 DiseaseOrPhenotypicFeature denotes MCL MESH:D020522
8038 471-476 DiseaseOrPhenotypicFeature denotes tumor MESH:D009369
8039 505-517 ChemicalEntity denotes temsirolimus MESH:C401859
8040 652-664 ChemicalEntity denotes temsirolimus MESH:C401859
8041 717-729 ChemicalEntity denotes temsirolimus MESH:C401859
8042 740-745 DiseaseOrPhenotypicFeature denotes tumor MESH:D009369
8043 849-854 DiseaseOrPhenotypicFeature denotes tumor MESH:D009369
8044 897-909 ChemicalEntity denotes temsirolimus MESH:C401859
8045 956-961 DiseaseOrPhenotypicFeature denotes tumor MESH:D009369
8046 989-993 GeneOrGeneProduct denotes VEGF NCBIGene:7422
8047 1083-1091 DiseaseOrPhenotypicFeature denotes necrotic MESH:D009336
8048 1132-1144 ChemicalEntity denotes temsirolimus MESH:C401859
8049 1160-1172 ChemicalEntity denotes temsirolimus MESH:C401859
8050 1181-1186 DiseaseOrPhenotypicFeature denotes tumor MESH:D009369
8051 1272-1284 ChemicalEntity denotes temsirolimus MESH:C401859
8052 1288-1293 DiseaseOrPhenotypicFeature denotes tumor MESH:D009369
8053 1368-1371 DiseaseOrPhenotypicFeature denotes MCL MESH:D020522

LitCoin_Mondo

Id Subject Object Predicate Lexical cue mondo_id
T1 69-89 DiseaseOrPhenotypicFeature denotes mantle cell lymphoma 0018876
T2 81-89 DiseaseOrPhenotypicFeature denotes lymphoma 0005062
T3 91-111 DiseaseOrPhenotypicFeature denotes Mantle cell lymphoma 0018876
T4 103-111 DiseaseOrPhenotypicFeature denotes lymphoma 0005062
T5 123-127 DiseaseOrPhenotypicFeature denotes rare 0021136
T6 151-180 DiseaseOrPhenotypicFeature denotes B-cell non-Hodgkin's lymphoma 0015759
T7 172-180 DiseaseOrPhenotypicFeature denotes lymphoma 0005062

LitCoin-GeneOrGeneProduct-v0

Id Subject Object Predicate Lexical cue
T1 76-80 GeneOrGeneProduct denotes cell
T2 98-102 GeneOrGeneProduct denotes cell
T3 112-122 GeneOrGeneProduct denotes (MCL) is a
T4 123-127 GeneOrGeneProduct denotes rare
T5 153-157 GeneOrGeneProduct denotes cell
T6 386-390 GeneOrGeneProduct denotes mTOR
T7 440-444 GeneOrGeneProduct denotes case
T8 471-476 GeneOrGeneProduct denotes tumor
T9 583-587 GeneOrGeneProduct denotes case
T10 589-594 GeneOrGeneProduct denotes lymph
T11 595-599 GeneOrGeneProduct denotes node
T12 740-745 GeneOrGeneProduct denotes tumor
T13 746-750 GeneOrGeneProduct denotes cell
T14 773-783 GeneOrGeneProduct denotes cell cycle
T15 784-790 GeneOrGeneProduct denotes arrest
T16 804-810 GeneOrGeneProduct denotes induce
T17 849-854 GeneOrGeneProduct denotes tumor
T18 855-860 GeneOrGeneProduct denotes cells
T19 862-867 GeneOrGeneProduct denotes Apart
T20 953-961 GeneOrGeneProduct denotes of tumor
T21 989-993 GeneOrGeneProduct denotes VEGF
T22 1038-1045 GeneOrGeneProduct denotes limited
T23 1055-1060 GeneOrGeneProduct denotes areas
T24 1078-1082 GeneOrGeneProduct denotes post
T25 1083-1091 GeneOrGeneProduct denotes necrotic
T26 1173-1180 GeneOrGeneProduct denotes reduced
T27 1181-1186 GeneOrGeneProduct denotes tumor
T28 1288-1293 GeneOrGeneProduct denotes tumor

LitCoin-GeneOrGeneProduct-v2

Id Subject Object Predicate Lexical cue
T1 76-80 GeneOrGeneProduct denotes cell
T2 98-102 GeneOrGeneProduct denotes cell
T3 123-127 GeneOrGeneProduct denotes rare
T4 153-157 GeneOrGeneProduct denotes cell
T5 386-390 GeneOrGeneProduct denotes mTOR
T6 746-750 GeneOrGeneProduct denotes cell
T7 773-783 GeneOrGeneProduct denotes cell cycle
T8 784-790 GeneOrGeneProduct denotes arrest
T9 862-867 GeneOrGeneProduct denotes Apart
T10 989-993 GeneOrGeneProduct denotes VEGF
T11 1038-1045 GeneOrGeneProduct denotes limited
T12 1078-1082 GeneOrGeneProduct denotes post
T13 1083-1091 GeneOrGeneProduct denotes necrotic
T14 1173-1180 GeneOrGeneProduct denotes reduced

LitCoin-Disease-MeSH

Id Subject Object Predicate Lexical cue originalLabel
T1 69-89 DiseaseOrPhenotypicFeature denotes mantle cell lymphoma D020522
T2 91-111 DiseaseOrPhenotypicFeature denotes Mantle cell lymphoma D020522
T3 113-116 DiseaseOrPhenotypicFeature denotes MCL D020522
T4 158-180 DiseaseOrPhenotypicFeature denotes non-Hodgkin's lymphoma D008228
T5 353-356 DiseaseOrPhenotypicFeature denotes MCL D020522
T6 459-462 DiseaseOrPhenotypicFeature denotes MCL D020522
T7 471-476 DiseaseOrPhenotypicFeature denotes tumor D009369
T8 740-745 DiseaseOrPhenotypicFeature denotes tumor D009369
T9 849-854 DiseaseOrPhenotypicFeature denotes tumor D009369
T10 956-961 DiseaseOrPhenotypicFeature denotes tumor D009369
T11 1181-1186 DiseaseOrPhenotypicFeature denotes tumor D009369
T12 1288-1293 DiseaseOrPhenotypicFeature denotes tumor D009369
T13 1368-1371 DiseaseOrPhenotypicFeature denotes MCL D020522

LitCoin-GeneOrGeneProduct-v3

Id Subject Object Predicate Lexical cue
T1 386-390 GeneOrGeneProduct denotes mTOR
T2 989-993 GeneOrGeneProduct denotes VEGF
T3 1083-1091 GeneOrGeneProduct denotes necrotic

LitCoin_Mondo_095

Id Subject Object Predicate Lexical cue mondo_id
T1 69-89 DiseaseOrPhenotypicFeature denotes mantle cell lymphoma 0018876
T2 91-111 DiseaseOrPhenotypicFeature denotes Mantle cell lymphoma 0018876
T3 113-116 DiseaseOrPhenotypicFeature denotes MCL 0018876
T4 151-180 DiseaseOrPhenotypicFeature denotes B-cell non-Hodgkin's lymphoma 0015759
T5 353-356 DiseaseOrPhenotypicFeature denotes MCL 0018876
T6 459-462 DiseaseOrPhenotypicFeature denotes MCL 0018876
T7 471-476 DiseaseOrPhenotypicFeature denotes tumor 0005070
T8 740-745 DiseaseOrPhenotypicFeature denotes tumor 0005070
T9 849-854 DiseaseOrPhenotypicFeature denotes tumor 0005070
T10 956-961 DiseaseOrPhenotypicFeature denotes tumor 0005070
T11 1181-1186 DiseaseOrPhenotypicFeature denotes tumor 0005070
T12 1288-1293 DiseaseOrPhenotypicFeature denotes tumor 0005070
T13 1368-1371 DiseaseOrPhenotypicFeature denotes MCL 0018876

LitCoin-MeSH-Disease-2

Id Subject Object Predicate Lexical cue ID:
T1 69-89 DiseaseOrPhenotypicFeature denotes mantle cell lymphoma D020522
T2 91-111 DiseaseOrPhenotypicFeature denotes Mantle cell lymphoma D020522
T3 113-116 DiseaseOrPhenotypicFeature denotes MCL D020522
T4 158-180 DiseaseOrPhenotypicFeature denotes non-Hodgkin's lymphoma D008228
T5 353-356 DiseaseOrPhenotypicFeature denotes MCL D020522
T6 459-462 DiseaseOrPhenotypicFeature denotes MCL D020522
T7 471-476 DiseaseOrPhenotypicFeature denotes tumor D009369
T8 740-745 DiseaseOrPhenotypicFeature denotes tumor D009369
T9 849-854 DiseaseOrPhenotypicFeature denotes tumor D009369
T10 956-961 DiseaseOrPhenotypicFeature denotes tumor D009369
T11 1083-1091 DiseaseOrPhenotypicFeature denotes necrotic DISEASE
T12 1181-1186 DiseaseOrPhenotypicFeature denotes tumor D009369
T13 1288-1293 DiseaseOrPhenotypicFeature denotes tumor D009369
T14 1368-1371 DiseaseOrPhenotypicFeature denotes MCL D020522

LitCoin-MONDO_bioort2019

Id Subject Object Predicate Lexical cue #label
T1 69-89 DiseaseOrPhenotypicFeature denotes mantle cell lymphoma D020522
T2 91-111 DiseaseOrPhenotypicFeature denotes Mantle cell lymphoma D020522
T3 113-116 DiseaseOrPhenotypicFeature denotes MCL D020522
T4 158-180 DiseaseOrPhenotypicFeature denotes non-Hodgkin's lymphoma D008228
T5 353-356 DiseaseOrPhenotypicFeature denotes MCL D020522
T6 459-462 DiseaseOrPhenotypicFeature denotes MCL D020522
T7 471-476 DiseaseOrPhenotypicFeature denotes tumor D009369
T8 740-745 DiseaseOrPhenotypicFeature denotes tumor D009369
T9 849-854 DiseaseOrPhenotypicFeature denotes tumor D009369
T10 956-961 DiseaseOrPhenotypicFeature denotes tumor D009369
T11 1083-1091 DiseaseOrPhenotypicFeature denotes necrotic DISEASE
T12 1181-1186 DiseaseOrPhenotypicFeature denotes tumor D009369
T13 1288-1293 DiseaseOrPhenotypicFeature denotes tumor D009369
T14 1368-1371 DiseaseOrPhenotypicFeature denotes MCL D020522

LitCoin-Chemical-MeSH-CHEBI

Id Subject Object Predicate Lexical cue ID:
T1 42-54 ChemicalEntity denotes temsirolimus C401859
T2 370-382 ChemicalEntity denotes temsirolimus C401859
T3 505-517 ChemicalEntity denotes temsirolimus C401859
T4 652-664 ChemicalEntity denotes temsirolimus C401859
T5 717-729 ChemicalEntity denotes temsirolimus C401859
T6 897-909 ChemicalEntity denotes temsirolimus C401859
T7 1132-1144 ChemicalEntity denotes temsirolimus C401859
T8 1160-1172 ChemicalEntity denotes temsirolimus C401859
T9 1272-1284 ChemicalEntity denotes temsirolimus C401859

LitCoin-training-merged

Id Subject Object Predicate Lexical cue #label ID:
T9 1272-1284 ChemicalEntity denotes temsirolimus C401859
T8 1160-1172 ChemicalEntity denotes temsirolimus C401859
T7 1132-1144 ChemicalEntity denotes temsirolimus C401859
T6 897-909 ChemicalEntity denotes temsirolimus C401859
T5 717-729 ChemicalEntity denotes temsirolimus C401859
T4 652-664 ChemicalEntity denotes temsirolimus C401859
T3 505-517 ChemicalEntity denotes temsirolimus C401859
T2 370-382 ChemicalEntity denotes temsirolimus C401859
T1 42-54 ChemicalEntity denotes temsirolimus C401859
T32107 1083-1091 GeneOrGeneProduct denotes necrotic
T24384 989-993 GeneOrGeneProduct denotes VEGF
T13083 386-390 GeneOrGeneProduct denotes mTOR
T14 1368-1371 DiseaseOrPhenotypicFeature denotes MCL D020522
T13 1288-1293 DiseaseOrPhenotypicFeature denotes tumor D009369
T12 1181-1186 DiseaseOrPhenotypicFeature denotes tumor D009369
T11 1083-1091 DiseaseOrPhenotypicFeature denotes necrotic DISEASE
T10 956-961 DiseaseOrPhenotypicFeature denotes tumor D009369
T60562 849-854 DiseaseOrPhenotypicFeature denotes tumor D009369
T84005 740-745 DiseaseOrPhenotypicFeature denotes tumor D009369
T29527 471-476 DiseaseOrPhenotypicFeature denotes tumor D009369
T39724 459-462 DiseaseOrPhenotypicFeature denotes MCL D020522
T87530 353-356 DiseaseOrPhenotypicFeature denotes MCL D020522
T82415 158-180 DiseaseOrPhenotypicFeature denotes non-Hodgkin's lymphoma D008228
T73596 113-116 DiseaseOrPhenotypicFeature denotes MCL D020522
T13055 91-111 DiseaseOrPhenotypicFeature denotes Mantle cell lymphoma D020522
T79309 69-89 DiseaseOrPhenotypicFeature denotes mantle cell lymphoma D020522

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-90 Sentence denotes Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma.
TextSentencer_T2 91-181 Sentence denotes Mantle cell lymphoma (MCL) is a rare and aggressive type of B-cell non-Hodgkin's lymphoma.
TextSentencer_T3 182-281 Sentence denotes Patients become progressively refractory to conventional chemotherapy, and their prognosis is poor.
TextSentencer_T4 282-574 Sentence denotes However, a 38% remission rate has been recently reported in refractory MCL treated with temsirolimus, a mTOR inhibitor.Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after temsirolimus treatment, and a progression-free survival of 10 months.
TextSentencer_T5 575-673 Sentence denotes In this case, lymph node biopsies were performed before and six months after temsirolimus therapy.
TextSentencer_T6 674-861 Sentence denotes Comparison of the two biopsies showed that temsirolimus inhibited tumor cell proliferation through cell cycle arrest, but did not induce any change in the number of apoptotic tumor cells.
TextSentencer_T7 862-1005 Sentence denotes Apart from this cytostatic effect, temsirolimus had an antiangiogenic effect with decrease of tumor microvessel density and of VEGF expression.
TextSentencer_T8 1006-1153 Sentence denotes Moreover, numerous patchy, well-limited fibrotic areas, compatible with post-necrotic tissue repair, were found after 6-month temsirolimus therapy.
TextSentencer_T9 1154-1411 Sentence denotes Thus, temsirolimus reduced tumor burden through associated cytostatic and anti-angiogenic effects.This dual effect of temsirolimus on tumor tissue could contribute to its recently reported efficiency in refractory MCL resistant to conventional chemotherapy.
T1 0-90 Sentence denotes Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma.
T2 91-181 Sentence denotes Mantle cell lymphoma (MCL) is a rare and aggressive type of B-cell non-Hodgkin's lymphoma.
T3 182-281 Sentence denotes Patients become progressively refractory to conventional chemotherapy, and their prognosis is poor.
T4 282-574 Sentence denotes However, a 38% remission rate has been recently reported in refractory MCL treated with temsirolimus, a mTOR inhibitor.Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after temsirolimus treatment, and a progression-free survival of 10 months.
T5 575-673 Sentence denotes In this case, lymph node biopsies were performed before and six months after temsirolimus therapy.
T6 674-861 Sentence denotes Comparison of the two biopsies showed that temsirolimus inhibited tumor cell proliferation through cell cycle arrest, but did not induce any change in the number of apoptotic tumor cells.
T7 862-1005 Sentence denotes Apart from this cytostatic effect, temsirolimus had an antiangiogenic effect with decrease of tumor microvessel density and of VEGF expression.
T8 1006-1153 Sentence denotes Moreover, numerous patchy, well-limited fibrotic areas, compatible with post-necrotic tissue repair, were found after 6-month temsirolimus therapy.
T9 1154-1411 Sentence denotes Thus, temsirolimus reduced tumor burden through associated cytostatic and anti-angiogenic effects.This dual effect of temsirolimus on tumor tissue could contribute to its recently reported efficiency in refractory MCL resistant to conventional chemotherapy.

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 103-111 HP_0002665 denotes lymphoma
T2 132-142 HP_0000718 denotes aggressive
T3 158-180 HP_0012539 denotes non-Hodgkin's lymphoma
T4 162-180 HP_0012189 denotes Hodgkin's lymphoma
T5 172-180 HP_0002665 denotes lymphoma
T6 471-476 HP_0002664 denotes tumor
T7 740-745 HP_0002664 denotes tumor
T8 849-854 HP_0002664 denotes tumor
T9 956-961 HP_0002664 denotes tumor
T10 1181-1186 HP_0002664 denotes tumor
T11 1288-1293 HP_0002664 denotes tumor

Allie

Id Subject Object Predicate Lexical cue
SS1_20828385_1_0 91-111 expanded denotes Mantle cell lymphoma
SS2_20828385_1_0 113-116 abbr denotes MCL
AE1_20828385_1_0 SS1_20828385_1_0 SS2_20828385_1_0 abbreviatedTo Mantle cell lymphoma,MCL

UBERON-AE

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 69-75 http://purl.obolibrary.org/obo/UBERON_0006575 denotes mantle
PD-UBERON-AE-B_T2 589-594 http://purl.obolibrary.org/obo/UBERON_0002391 denotes lymph
PD-UBERON-AE-B_T3 589-599 http://purl.obolibrary.org/obo/UBERON_0000029 denotes lymph node
PD-UBERON-AE-B_T4 1092-1098 http://purl.obolibrary.org/obo/UBERON_0000479 denotes tissue
PD-UBERON-AE-B_T5 1294-1300 http://purl.obolibrary.org/obo/UBERON_0000479 denotes tissue

PubCasesHPO

Id Subject Object Predicate Lexical cue
AB1 103-111 HP:0002665 denotes lymphoma
TI1 81-89 HP:0002665 denotes lymphoma

PubCasesORDO

Id Subject Object Predicate Lexical cue
AB1 91-111 ORDO:52416 denotes Mantle cell lymphoma
AB2 113-116 ORDO:52416 denotes MCL
TI1 69-89 ORDO:52416 denotes mantle cell lymphoma
AB3 353-356 ORDO:52416 denotes MCL
AB4 459-462 ORDO:52416 denotes MCL
AB5 1368-1371 ORDO:52416 denotes MCL

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 69-75 http://purl.obolibrary.org/obo/UBERON_0006575 denotes mantle
PD-UBERON-AE-B_T2 91-97 http://purl.obolibrary.org/obo/UBERON_0006575 denotes Mantle
PD-UBERON-AE-B_T3 589-594 http://purl.obolibrary.org/obo/UBERON_0002391 denotes lymph
PD-UBERON-AE-B_T4 589-599 http://purl.obolibrary.org/obo/UBERON_0000029 denotes lymph node
PD-UBERON-AE-B_T5 1092-1098 http://purl.obolibrary.org/obo/UBERON_0000479 denotes tissue
PD-UBERON-AE-B_T6 1294-1300 http://purl.obolibrary.org/obo/UBERON_0000479 denotes tissue